Department of Pharmacology

A-Z Index | School of Medicine Quick Links

Find a Health Care Provider | Contact Us | Maps and Parking

Search:

Department of Pharmacology Faculty Members

Secondary and Training

	Timothy A. Benke Associate Professor M.D./Ph.D., 1995, Baylor College of Medicine Mechanisms of synaptic plasticity and impacts of development and epilepsy.
	Elan Z. Eisenmesser Assistant Professor Ph.D., 1998, Purdue Univ. Viral protein/host protein interactions, enzyme dynamics, and ligand/receptor interactions involved in cancer progression.
	Paul V. Fennessey Professor Ph.D., 1968, Massachusetts Institute of Technology Solutions to clinical problems using stable isotopes and mass spectrometry.
	Curt R. Freed Professor M.D., 1969, Harvard Univ. The dynamic role of dopamine in movement; neural transplantation for Parkinson’s disease.
	Robert M.D. Freedman Professor M.D., 1972, Harvard Univ. Central nervous system physiology and pharmacology and its application to clinical psychiatry.
	Anthony N. Gerber Professor M.D., Ph.D., 1998, Univ. of Washington Targeting the glucocorticoid receptor for the treatment of inflammatory disorders of the lung such as asthma.
	Lynn E. Heasley Professor Ph.D., 1985, Univ. of California, San Diego Investigating the role of MAP kinases and specific receptor tyrosine kinases in normal and transformed growth of lung epithelial cells using techniques of molecular and cell biology in lung epithelial cells and human lung cancer cell lines.
	Peter M. Henson Professor Ph.D., 1967, Cambridge Univ., UK Inflammatory process as a paradigm of complex interacting cell networks and communication molecules and as a component of human diseases.
	Paco Herson Associate Professor Ph.D., 1999, Univ. of Aberdeen, UK Basic translational research using neurophysiology, biochemistry, molecular biology, histology and neuro-behavior to elucidate the mechanisms of neuronal injury and identify therapeutic targets for protection and repair.
	Robert S. Hodges Professor Ph.D., 1971, Univ. of Alberta Structure-function studies of multi-protein complexes; de novo design of model proteins to test our understanding of protein folding and structure and to design proteins with the desired biological/immunological activities; synthetic peptide vaccines and .
	John W. Kappler Professor Ph.D., 1970, Brandeis Univ. The study of the interaction between the T cell receptor and its signal ligands.
	Jeffrey S. Kieft Associate Professor Ph.D., 1997, Univ. of California, Berkeley The way by which viral RNAs, with their diverse and dynamic structures, can hijack the machinery of an infected cell and using this information to understand basic biological processes..
	Christina C. Leslie Professor Ph.D., 1975, Univ. of Georgia Signal transduction mechanisms regulating phospholipase A2 activation and the production of lipid mediators of inflammation.
	Chuan-Yuan Li Professor Ph.D., 1993, Harvard Univ. Molecular mechanisms of tumor response to therapy; roles of stem cells in tumor response to therapy.
	Timothy A. McKinsey Associate Professor Ph.D., 1998, Vanderbilt Univ. Epigenetic regulation of heart failure; signaling and transcriptional mechanisms of muscle disease.
	Raphael A. Nemenoff Professor Ph.D., 1977, Cornell Univ. Signaling pathways controlling growth and differentiation of vascular smooth muscle cells; Role of eicosanoids in lung cancer.
	Dennis R. Petersen Professor Ph.D., 1974, Univ. of Wyoming Molecular mechanisms of chemical and drug toxicity.
	J. David Port Professor Ph.D., 1989, Univ. of Utah G-protein linked receptors and their regulation; regulation of mRNA stability.
	David W.H. Riches Professor Ph.D., 1979, Univ. of Birmingham Signal transduction by TNF receptor family members and their involvement in macrophage development; Regulation of myofibroblast and macrophage apoptosis and survival in pulmonary fibrosis and cystic fibrosis.
	Natalie J. Serkova Associate Professor Ph.D., 1996, Univ. of Bremen Animal Imaging (MRI, PET, CT); Magnetic Resonance Spectroscopy (MRS) based metabonomics; Cancer Metabolism and Physiology; Anti-Cancer Drugs; Ischemia/Reperfusion in Organs.
	James M. Sikela Professor Ph.D., 1983, Case Western Reserve Univ. Neurogenomics; disease gene discovery; human genome evolution and variation.
	Dan Theodorescu Professor and Director of the Univ. of Colorado Comprehensive Cancer Center M.D., 1986, Queen's Univ. Faculty of Health Sciences; Ph.D., 1993, Univ. of Toronto I'm a physician scientist. Our translational molecular biology laboratory focuses on identifying the molecular mechanisms leading to bladder cancer metastasis and their potential applications to patients with this disease. Our group is at the forefront of the development of biomarkers and therapeutics in bladder cancer. My clinical practice is limited to bladder cancer management including surgery such as radical cystectomy using state of the art robotic techniques (i.e. da Vinci).
	Dennis R. Voelker Professor Ph.D., 1978, Oak Ridge National Laboratory Phospholipid transport processes in eukaryotic cells. Pulmonary surfactant proteins – structure and function.
	Xiao-Jing Wang Professor M.D., 1984, Beijing Medical Univ. TGF-beta signal transduction, molecular mechanisms of cancer development and progression, functions of tumor suppressors and oncogenes.
	Mary Weiser-Evans Associate Professor Ph.D., 1992, Colorado State Univ. Defining the molecular signaling mechanisms regulating vascular smooth muscle cell function in the setting of vascular fibroproliferative diseases, including restenosis and pulmonary hypertension.